December 12, 2022Nature Reviews Endocrinology
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Authors
Discussion
Loading...
Member takes
Implication
Narrative review reveals distinct extrapancreatic cardiovascular and metabolic effects of GIP and GLP-1 in cardiometabolic models, highlighting complementary targets for dual-incretin therapy.
Key Points
- To compare and contrast the direct extrapancreatic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) on the cardiovascular system and adipose tissue.
- Synthesized molecular, preclinical, and clinical evidence evaluating the extrapancreatic signaling of GIP and GLP-1 receptors.
- Analyzed differential mechanisms across vascular endothelium, cardiac tissue, adipose lipid turnover, and systemic inflammation.
- GLP-1 receptor activation consistently drives vascular endothelial protection, suppresses plaque inflammation, and lowers systemic blood pressure.
- GIP exerts distinct regulatory actions on white adipose tissue perfusion and lipid clearance while modulating cardiac energy balance, differing qualitatively from GLP-1 signaling.
- Dual activation of GIP and GLP-1 pathways produces additive cardiometabolic benefits exceeding those achieved through single incretin receptor stimulation alone.
Cite This Study
Hammoud et al. (2022) studied this question.